Medifast (MED) Tops Q1 EPS by 9c; Guides

Medifast (NYSE: MED) reported Q1 EPS of $0.42, $0.09 better than the analyst estimate of $0.33. Revenue for the quarter came in at $72.35 million versus the consensus estimate of $69.31 million.

"We are pleased with our start to 2016, particularly as momentum accelerated in our Take Shape For Life business segment," said Michael C. MacDonald, Medifast Chairman and Chief Executive Officer. "This, combined with our team's efforts to efficiently operate the business, fueled our financial performance and resulted in both revenue and profitability above our expectations for the first quarter. Going forward, we remain focused on taking steps to optimize each of our business units, by differentiating products, programs, and service offerings. We believe Medifast is well-positioned with the strategies in place and a strong balance sheet to drive profitability and enhanced shareholder returns."

GUIDANCE:

Medifast sees Q2 2016 EPS of $0.50-$0.53, versus the consensus of $0.48. Medifast sees Q2 2016 revenue of $70-73 million, versus the consensus of $70.32 million.

Medifast sees FY2016 EPS of $1.75-$1.80, versus the consensus of $1.74. Medifast sees FY2016 revenue of $275-282 million, versus the consensus of $275.65 million.

For earnings history and earnings-related data on Medifast (MED) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Star Equity Holdings (STRR) Misses Q2 EPS by 8c
• Hydrofarm Holdings Group, Inc. (HYFM) Misses Q2 EPS by 134c